SCHEMBL24136649

SCHEMBL24136649

COc1cc2cc[nH]c(=O)c2c(C)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
CHEK1 O14757 4/20 0.40
MAOA P21397 1/20 0.40
KDM4E B2RXH2 2/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA7 P43166 2/20 0.40
MCL1 Q07820 2/20 0.40
CA9 Q16790 2/20 0.40
CA13 Q8N1Q1 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CA2 P00918 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CYP2C19 P33261 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15329220 0.73 PDE3B (0.50) CHEK1MAOAKDM4EMEN1ALDH1A1
SCHEMBL21593366 0.72 CHEK1 (0.48) CHEK1
SCHEMBL3951034 0.70 ROCK1 (0.46) MAOAKDM4EMCL1ALDH1A1HPGD
SCHEMBL1204984 0.70 ROCK1 (0.55) MAPTKDM4EALDH1A1HPGDTUBB4A
SCHEMBL18257252 0.69 PDE3B (0.40) MAPTKDM4EMCL1MEN1ALDH1A1
SCHEMBL4296227 0.69 CHEK1 (0.54) CHEK1KDM4ECA12CA1CA7
SCHEMBL30466409 0.68 PARP1 (0.43) CHEK1KDM4EALDH1A1CYP2C9HPGD
SCHEMBL24136691 0.68 PARP1 (0.43) CHEK1KDM4EALDH1A1CYP2C9HPGD
SCHEMBL9315325 0.68 TUBB4A (0.41) MAPTKDM4ECA12CA1CA7
SCHEMBL29039486 0.68 ALDH1A1 (0.58) MAPTCHEK1KDM4EALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116194108-B Novel dioxoisoquinolinone derivatives and use thereof 韩美药品株式会社 2025-05-30 CN disclosed
CN-113423710-B Novel heterocyclic tricyclic derivative compounds and use thereof 韩美药品株式会社 2024-06-14 CN disclosed
CN-116194108-A Novel dioxoisoquinolinone derivatives and use thereof 韩美药品株式会社 2023-05-30 CN disclosed
US-11535629-B2 Dioxoloisoquinolinone derivatives and use thereof HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-12-27 US disclosed
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-05-05 US disclosed
EP-3929199-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME Hanmi Pharmaceutical Co., Ltd. (KR) 2021-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11535629-B2 Dioxoloisoquinolinone derivatives and use thereof EZH2, EZH1, EED MAPT 1430/4885CHEK1 3195/4885MAOA 3143/4885
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME EZH2, EZH1, BMI1 MAPT 4574/4885CHEK1 3978/4885MAOA 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.